HRP20180049T1 - Derivati diazakarbazola kao tau-pet ligandi - Google Patents

Derivati diazakarbazola kao tau-pet ligandi Download PDF

Info

Publication number
HRP20180049T1
HRP20180049T1 HRP20180049TT HRP20180049T HRP20180049T1 HR P20180049 T1 HRP20180049 T1 HR P20180049T1 HR P20180049T T HRP20180049T T HR P20180049TT HR P20180049 T HRP20180049 T HR P20180049T HR P20180049 T1 HRP20180049 T1 HR P20180049T1
Authority
HR
Croatia
Prior art keywords
formula
compound
image
tau
compounds
Prior art date
Application number
HRP20180049TT
Other languages
English (en)
Croatian (hr)
Inventor
Luca Gobbi
Henner Knust
Matthias Koerner
Dieter MURI
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20180049T1 publication Critical patent/HRP20180049T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20180049TT 2013-10-08 2014-10-06 Derivati diazakarbazola kao tau-pet ligandi HRP20180049T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187764 2013-10-08
PCT/EP2014/071283 WO2015052105A1 (en) 2013-10-08 2014-10-06 Diazacarbazole derivatives as tau-pet-ligands
EP14781169.9A EP3055308B1 (en) 2013-10-08 2014-10-06 Diazacarbazole derivatives as tau-pet-ligands

Publications (1)

Publication Number Publication Date
HRP20180049T1 true HRP20180049T1 (hr) 2018-02-09

Family

ID=49301396

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180049TT HRP20180049T1 (hr) 2013-10-08 2014-10-06 Derivati diazakarbazola kao tau-pet ligandi

Country Status (32)

Country Link
US (2) US10004817B2 (OSRAM)
EP (1) EP3055308B1 (OSRAM)
JP (1) JP6194416B2 (OSRAM)
KR (1) KR101770531B1 (OSRAM)
CN (1) CN105358558B (OSRAM)
AR (1) AR097931A1 (OSRAM)
AU (1) AU2014333996B2 (OSRAM)
CA (1) CA2917191C (OSRAM)
CL (1) CL2016000728A1 (OSRAM)
CR (1) CR20150663A (OSRAM)
DK (1) DK3055308T3 (OSRAM)
EA (1) EA028483B1 (OSRAM)
ES (1) ES2657121T3 (OSRAM)
HR (1) HRP20180049T1 (OSRAM)
HU (1) HUE035413T2 (OSRAM)
IL (1) IL243249A0 (OSRAM)
LT (1) LT3055308T (OSRAM)
MA (1) MA38935B1 (OSRAM)
MX (1) MX373153B (OSRAM)
MY (1) MY190196A (OSRAM)
NO (1) NO3055308T3 (OSRAM)
PE (1) PE20160159A1 (OSRAM)
PH (1) PH12016500249A1 (OSRAM)
PL (1) PL3055308T3 (OSRAM)
PT (1) PT3055308T (OSRAM)
RS (1) RS56777B1 (OSRAM)
SG (1) SG11201602786UA (OSRAM)
SI (1) SI3055308T1 (OSRAM)
TW (1) TWI513698B (OSRAM)
UA (1) UA116164C2 (OSRAM)
WO (1) WO2015052105A1 (OSRAM)
ZA (1) ZA201509013B (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2247558T (lt) 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
NO3055308T3 (OSRAM) 2013-10-08 2018-04-21
SI3143011T1 (sl) 2014-05-13 2021-08-31 F. Hoffmann-La Roche Ag Devterirane heterociklične spojine in njihova uporaba kot kontrastna sredstva
CA2973648C (en) 2015-02-02 2023-09-26 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
EP3118202A1 (en) 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
EP3322707A1 (en) 2015-07-15 2018-05-23 AC Immune SA Novel imaging compounds
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
IL264239B (en) * 2016-07-22 2022-08-01 Ac Immune Sa Compounds for imaging tau protein aggregates
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
CN109689653B (zh) * 2016-09-09 2022-04-12 豪夫迈·罗氏有限公司 用于制备2-(6-硝基吡啶-3-基)-9H-二吡啶并[2,3-b;3’,4’-d]吡咯的方法
JP7260552B2 (ja) * 2018-01-24 2023-04-18 エーシー・イミューン・エス・アー Pet画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用
US20210038747A1 (en) * 2018-01-24 2021-02-11 Ac Immune Sa Novel method of preparing an imaging compound
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
LT2247558T (lt) * 2008-02-14 2022-04-11 Eli Lilly And Company Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui
US20110124654A1 (en) 2008-06-11 2011-05-26 Huifen Chen Diazacarbazoles and methods of use
EP2323697A2 (en) * 2008-07-24 2011-05-25 Siemens Medical Solutions USA, Inc. Imaging agents useful for identifying ad pathology
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (en) * 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
US20110183938A1 (en) * 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US20150368244A1 (en) * 2011-01-31 2015-12-24 Genentech, Inc. Diazacarbazoles and methods of use
NO3055308T3 (OSRAM) * 2013-10-08 2018-04-21

Also Published As

Publication number Publication date
CR20150663A (es) 2016-01-27
CA2917191A1 (en) 2015-04-16
LT3055308T (lt) 2018-02-12
HUE035413T2 (en) 2018-05-02
MA38935A1 (fr) 2016-04-29
CA2917191C (en) 2021-08-10
AU2014333996B2 (en) 2018-03-15
CL2016000728A1 (es) 2016-11-11
PH12016500249B1 (en) 2016-05-16
MY190196A (en) 2022-04-04
EA201690515A1 (ru) 2016-07-29
PT3055308T (pt) 2018-01-18
EP3055308A1 (en) 2016-08-17
TW201520212A (zh) 2015-06-01
AR097931A1 (es) 2016-04-20
MA38935B1 (fr) 2016-12-30
UA116164C2 (uk) 2018-02-12
IL243249A0 (en) 2016-02-29
PH12016500249A1 (en) 2016-05-16
NO3055308T3 (OSRAM) 2018-04-21
NZ714831A (en) 2021-09-24
US11058781B2 (en) 2021-07-13
MX2016002234A (es) 2016-06-06
AU2014333996A1 (en) 2015-12-24
PL3055308T3 (pl) 2018-03-30
US20180326099A1 (en) 2018-11-15
ES2657121T3 (es) 2018-03-01
JP6194416B2 (ja) 2017-09-06
EP3055308B1 (en) 2017-11-22
SG11201602786UA (en) 2016-05-30
SI3055308T1 (en) 2018-03-30
US10004817B2 (en) 2018-06-26
MX373153B (es) 2020-04-21
JP2016534979A (ja) 2016-11-10
KR20160047552A (ko) 2016-05-02
WO2015052105A1 (en) 2015-04-16
RS56777B1 (sr) 2018-04-30
PE20160159A1 (es) 2016-03-18
EA028483B1 (ru) 2017-11-30
US20160220712A1 (en) 2016-08-04
CN105358558B (zh) 2017-09-26
CN105358558A (zh) 2016-02-24
DK3055308T3 (en) 2018-01-22
KR101770531B1 (ko) 2017-08-22
ZA201509013B (en) 2016-10-26
HK1215574A1 (zh) 2016-09-02
TWI513698B (zh) 2015-12-21

Similar Documents

Publication Publication Date Title
SI3055308T1 (en) Diazacarbazole derivatives as tau-pet-ligands
HRP20201984T1 (hr) Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
HRP20200666T1 (hr) Derivati piridin-2(1h)-on kinolinona kao inhibitori mutirane izocitrat dehidrogenaze
Wickstrøm et al. The development of an automated and GMP compliant FASTlab™ Synthesis of [18F] GE‐180; a radiotracer for imaging translocator protein (TSPO)
JP6245981B2 (ja) 含水有機溶媒中の18f−標識化トレーサーの合成
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
HRP20210183T1 (hr) 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
JP2022136074A (ja) 新規製剤及び合成方法
HRP20150885T1 (hr) Postupak za pripremu 4-{4-[({[4-kloro-3-(trifluorometil)-fenil]amino}karbonil)amino]-3-fluorofenoksi}-n-metilpiridin-2-karboksamida, njegovih soli i monohidrata
HRP20171167T1 (hr) Priprava intermedijera pirimidina koji služe za proizvodnju macitentana
GB2519026B (en) Preparation of 18F-fluciclovine
DK3068765T5 (en) PROCEDURE FOR FLUORING COMPOUNDS
JP2017081847A (ja) フルテメタモルの製造方法
JP5688808B2 (ja) 高速フルオロメチル化法及びそれを利用したpetトレーサーの製造方法
Verbeek et al. Synthesis and preclinical evaluation of [11C] D617, a metabolite of (R)-[11C] verapamil
JP2014520075A5 (OSRAM)
Sobrio et al. Automated radiosynthesis of [18F] ML-10, a PET radiotracer dedicated to apoptosis imaging, on a TRACERLab FX-FN module
WO2015143019A3 (en) Gaseous f-18 technologies
JP7022132B2 (ja) 固相コンディショニング
CA2929940A1 (en) Process for fluorinating compounds
Rami-Mark et al. Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter:[11C] IPCIT and [18F] FE@ IPCIT
HRP20240343T1 (hr) Postupak i međuprodukt u pripravi oksetan-2-ilmetanamina
Airaksinen et al. [11C] Cyclopropyl-FLB 457: a PET radioligand for low densities of dopamine D2 receptors
JP6571642B2 (ja) 大環状化合物及びそのアニオンクエンチャーとしての使用
JP2023539197A (ja) Pet放射性トレーサとしての[18f]標識イミダゾピリジン誘導体